In the past five years, multiple structurally and functionally distinct androgen receptor (AR)
splice variants have been decoded and characterized. The mature transcripts for the …

As prostate cancer (PCa) progresses to the lethal castration resistant and metastatic form,
genetic and epigenetic adaptation, clonal selection, and evolution of the tumor …

Background The androgen receptor (AR) is a key prostate cancer drug target. Suppression
of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing …

Androgen receptor (AR) splice variants lacking the ligand binding domain (ARVs), originally
isolated from prostate cancer cell lines derived from a single patient, are detected in normal …

Purpose In this review, we summarize the importance of AR variants with a particular focus
on clinically relevant members of this family. Methods A non-systematic literature review was …

Upregulation of constitutively-active androgen receptor splice variants (AR-Vs) has been
implicated in AR-driven tumor progression in castration-resistant prostate cancer. To date …

Androgen receptor splice variants (AR-V) are implicated in resistance of prostate cancer to
androgen-directed therapies. When expressed alone in cells, some AR-Vs (eg, AR-V7) …

Simple Summary Androgen receptor splice variants (AR-Vs) play an important role in
prostate cancer progression, especially as a putative resistance mechanism against AR …

While there are myriad mechanisms of primary and acquired resistance to conventional and
next-generation hormonal therapies in prostate cancer, the potential role of androgen …

Androgen receptor splice variants (AR-Vs)—which are expressed in castration-resistant
prostate cancer (CRPC) cell lines and clinical samples—lack the C-terminal ligand-binding …